TCT
REGN icon

TIAA CREF Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

TIAA CREF Trust’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-10,007
Closed -$3.61M – 352
2016
Q1 		$3.61M Sell
10,007
-21
-0.2% -$8.65K 0.04% 141
2015
Q4 		$5.44M Sell
10,028
-991
-9% -$537K 0.06% 127
2015
Q3 		$5.13M Sell
11,019
-232
-2% -$125K 0.06% 127
2015
Q2 		$5.74M Sell
11,251
-365
-3% -$178K 0.06% 124
2015
Q1 		$5.24M Sell
11,616
-727
-6% -$308K 0.06% 128
2014
Q4 		$5.06M Sell
12,343
-370
-3% -$146K 0.06% 126
2014
Q3 		$4.58M Buy
12,713
+1,765
+16% +$592K 0.06% 128
2014
Q2 		$3.09M Sell
10,948
-10
-0.1% -$2.96K 0.04% 148
2014
Q1 		$3.29M Sell
10,958
-1,962
-15% -$604K 0.05% 139
2013
Q4 		$3.56M Buy
+12,920
New +$3.72M 0.06% 132

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TIAA CREF Trust's REGN Position: Q2 2016 in Review

TIAA CREF Trust sold out of Regeneron Pharmaceuticals (REGN) in Q2 2016, closing a stake of 10,007 shares — an estimated $3.61M sold.

TIAA CREF Trust first reported a position in REGN in Q4 2013 and held it in 10 quarters. The position peaked at $5.74M in Q2 2015. 542 funds tracked by Wall St. Rank hold REGN as of Q2 2016.

  • TIAA CREF Trust reported no remaining Regeneron Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • TIAA CREF Trust sold 10,007 Regeneron Pharmaceuticals shares in Q2 2016, an estimated $3.61M.
  • TIAA CREF Trust first reported a position in Regeneron Pharmaceuticals in Q4 2013 and held it in 10 quarters.
  • TIAA CREF Trust's Regeneron Pharmaceuticals position peaked at $5.74M in Q2 2015.
  • 542 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2016.

Based on TIAA CREF Trust's 13F filing for Q2 2016, filed 21 Jul 2016.